# INNOVARE JOURNAL OF AYURVEDIC SCIENCES



Vol 1, Issue 1, 2013 ISSN-2321-6824

Research Article

# CLINICAL TRIAL OF DRUG VYAN UTKSHEPAHARA GHAN VATI (KALPIT YOG) IN DIABETES (NIDDM) INDUCED HYERTENSION

# GUPTA MANOJ KUMAR\*1, GAUR DINESH SINGH2, SHARMA SHRIKRISHNA3, SINGH RUCHI4,

<sup>1</sup>Lecturer, Department of Roga and Vikriti Vijnana,Government Ashtang Ayurvedic College and Hospital, Lokmanya Nagar, Indore, Madhyapradesh, India. <sup>2</sup>Lecturer, Department of Shalakya, Government Ashtang Ayurvedic College and Hospital, Lokmanya Nagar, Indore, Madhyapradesh, India. <sup>3</sup>Ex Associate Professor Department of Roga and Vikriti Vijnana, National Institute of Ayurveda, Jaipur, Rajasthan, India.4-IMO (Ayurveda), ESIC Model hospital, Nanda nagar, Indore, Madhya pradesh, IndiaEmail - drmanoj.gupta505@g mail.com

Received: 12 April 2013, Revised and Accepted:26 April 2013

#### ABSTRACT

Due to the unwholesome diet, sedentary life style, day by day our country is facing the increasing burden of the patients of diabetes induced high blood pressure, and obesity. Our country is becoming the capital of these diseases. These diseases mostly treated by allopathic medicines which are having considerable side effects and could not be used on long term basis. So conclusion is that in these disease, the dose of allopathic medicines and disease gradually progresses and in addition due to the side effects of allopathic medicines, it is better that these diseases should be treated by *Ayurvedic* medicines

Keywords: Vyan vikriti, vyan bala, Raktavritta vata, Raktagata vata, Dhamani Pratichaya, Siragata vata, Rasabhara, Dhamani Prapurnata, Vyanavrita vata etc.

#### INTRODUCTION

High blood pressure (hypertension) is designated as either essential (primary) hypertension or secondary hypertension and is defined as a consistently elevated blood pressure exceeding 140/90 mm Hg. In essential hypertension (95% of people with hypertension) no specific cause is found. While secondary hypertension (5% of people with hypertension) is caused by an abnormality somewhere in the body such as in the kidney, adrenal gland & aortic artery etc. High blood pressure is called "the Silent Killer" because it often causes no symptoms for many years, even decades, until it finally damages certain critical organs like kidney, brain, blood vessel, eye etc. Mostly its diagnosis is ruled out all of sudden when the person comes in contact of doctor or health worker etc. Heightened public awareness and screening of the population are necessary to detect hypertension early enough so it can be treated before critical organs are damaged. It is one of the major risk factors for cardiovascular mortality, which accounts for 20-25% of all deaths.

#### Aims and objectives:

- 1. To evaluate the efficacy of  $\it Ayurvedic$  drugs as compare to modern drug, like Atenolol 50 mg.
- 2. To overcome the harmful effects of Allopathic drug in those patient which are suffering Diabetes (NIDDM) induced hypertension from long duration?

# **Selection of Patients**

A total Ninety patient of Hypertension for clinical trial was screened out from OPD & IPD Government Ashtang College and local regional area of Lokmanya Nagar Indore M.P.

**Grouping of Patient:** Screened patient or the case registered for the study were randomly divided into three groups

**Group A:** This group of 30 patients will be given the trial of drug *Vyan utkshepahara ghan vati* Diabetes (NIDDM) induced hypertension.

**Group B:** This group of 30 patients will be given the trial drug Atenolol 50 mg.

**Group C:** This group of 30 patients will be Placebo (VUHGV2)

During the trial and follow up study the patients were assessed on the following parameter.

## Inclusion criteria

Patients with persistent rise of blood pressure with clinical picture of diabetes induced high blood pressure have been selected for the research work.

# Exclusion criteria

Patients' with severe grade of Hypertension. Mild or Moderate Hypertension associated with other diseases like Cardiomyopathy, Cardiac failure, Coronary artery disease, Heartblock, Cerebrovasculardisease, Encephalopathy, Preclampsia/eclampsia, Renal disease, Diabetes mellitus and Retinopathy.

#### Diagnostic criteria

**To obtain diagnosis**: On each occasion at least 2 sets of blood pressure reading, separated by 20-30 minutes intervals was taken. On the basis of  $6^{th}$  and  $7^{th}$  joint national committee on detection evaluation & treatment of high blood pressure.

# Subjective (clinical) Parameters

JNC 6 Category		JNC 7 Category
	SBP / DBP in mm Hg	
Optimal	< 120 / 80	$\rightarrow$ Normal
Normal Border line	120 - 129 / 80 - 84 130 - 139 / 85-89	→ Pre hypertension
Hypertension	≥ 140 / 90	Hypertension
Stage 1 (mild) Stage2 (moderate)	140 - 159 / 90 - 99 160 - 179 / 100 - 109	→ Stage I
Stage 3	≥ 180 / 110	→ Stage II

Sirahashoola (Headache) Bhrama (Dizziness), Hraddravata (Palpitation), Krodha (Irritability),

Klama(Fatigue), Anidra(Insomnia), Swasakrichhrata(Dyspnoea), Nisham utrata(Nocturia), Bahumutrata(Polyuria), Karnanada(Tinitus), Atisweda (Sweating) and Murchha (Syncope) symptoms have been screened for diagnosis of Hypertension.

#### **Assessment of Symptoms:**

Symptoms of the disease were assessed before and after the treatment on the basis of following criteria.

Not Pres	ent/Absence of Symptom	0	0
Very mil	d	1	25%
Mild		2	50%
Moderat	e	3	75%
Severe		4	100%

**Assessment of Blood Pressure Reduction** 

The results of the treatment were assessed as striking, wonderful, nice and fair at the end of treatment. The parameters of the assessment were taken as follows: -

**Striking:** An excellent response to therapy when the fall in D.B.P. was found >20 mm Hg or more, S.B.P. >40 mm Hg.

**Wonderful:** When the patient was noticed with a good response to therapy when fall in D.B.P. was found 11-20 mm Hg. S.B.P. was 21-40 mm. Hg.

**Nice:** The response is named Nice when the fall in D.B.P. was 6 -10 m; S.B.P. was 11-20 mm. Hg.

Fair: When the response falls in D.B.P. up to 5 mm Hg, S.B.P. was up to 10 mm Hg.

# **Objective (Laboratory) Parameters**

Complete Haemogram: Hb gm % TLC, DLC, ESR

**Biochemical examination:** S.urea, S.creatinine, Blood sugar fasting Lipid profile (S. cholesterol, S. triglyceride, S. HDL, S. LDL, S. VLDL

 $\boldsymbol{\mathsf{ECG}}$  - The entire test mentioned here has been done before and after treatment.

#### Ingredients of Vyan utkshepahara ghan vati

Drug	Latin name	Proportion
Shankhapushpi	(convolvulus pluricaulis)	Equal part

Punarnava	(Boerhavia diffusa)	"
Vacha	(Acorus calamus)	"
Shunthi	(zingiber officinale)	"
Kutaki	(Picrohiza Kurroa)	"
Patol	(Trichoasathes dioica)	"
Gugglu	(Commiphora mukul)	"
Arjun	(Terminalia arjuna)	"
Karela	(Momordia Charantia)	"
Jamun	(Syzygium Cumini)	"
Gudhchi	(Tinospora Cardifolia)	n n

## PREPARATION OF TRIAL DRUG

*Vyan utkshepahara ghan vati: Vyan utkshepahara ghan vati* was manufactured & standardized according to vati preparation method by classical method.

**Method of preparation:** The coarse powder of the above mentioned quantity of drugs had been taken separately according to the number of patients & then *Kasaya* followed by *Ghanasatva* is prepared by classical method & then pills (each pill 500 mg) are prepared & dried.

Dose	-	1 gm BD
Duration	-	2 months
Anupana	-	Luke warm water

**Follow up:** All the 90 patients of O.P.D. and I.P.D. level reviewed after two-month treatment. And on every review, blood pressure was measured in sitting posture for follow up records. Patients will be followed up after two month.

# **Observation and Results**

The samples of 90 patients diabetes induced high blood pressure were selected and sub divided into 3 groups of 30 patients each. The treatment was observed according to the plan of the study. All the results were derived after execution of statistical techniques. The effect of each therapy is presented as follows: -

Effect of *Vyan utkshepahara ghan vati*, Tab. Atenolol 50 mg and Placebo on S.B.P.


Table No.: 1 Showing the statistically analysis of the effect of trial drug, control drug, and placebo on S.B.P.

	Mean		Mean Diff.	Moon 0/		CD	CE		_	Results
Group	BT	AT	Mean Din.	Mean %	11	SD	3E	ι	þ	Results
A	159.67	145.53	14.14	8.85	30	13.07	2.39	5.91	< 0.001	HS
В	157.73	139.73	18.00	11.41	30	8.085	1.476	12.19	< 0.001	HS
С	156.6	153.03	3.56	2.27	30	12.12	2.21	1.61	< 0.1	IS

Note: HS: Highly Significant, S: Significant, IS: Insignifican

In group A 30 patients were investigated for S.B.P. and an initial mean score of 159.67 mm of Hg was measured, after 2 month's treatment of *Vyan utkshepahara ghan vati*, it reduced 145.53 mm of Hg with a mean difference of 14.14 mm of Hg with 8.85% of relief, it is highly significant (t = 5.91, P<0.001).

Group 'B'30 patients were investigated for initial mean score of S.B.P. was measured 157.73 mm of Hg and it reduced to 139.73 mm of Hg with 2 month treatment of atenolol 50 mg and mean difference of 18.00 mm of Hg and 11.41% of relief was observed. It is highly significant (t = 12.19, P<0.001).



Initial mean score of Group C (for30 patients) S.B.P. was measured

156.6~mm of Hg and after 2 month treatment of placebo is reduced to 153.03~mm of Hg and a mean different of 3.56~mm of Hg was found and

2.27% of relief was found. It is insignificant (t =1.61, P<0.1)

Effect of Vyan utkshepahara ghan vati, Tab. Atenolol 50 mg and Placebo on D.B.P.

Table 2: Showing the statistically analysis of the effect of *Vyan utkshepahara ghan vati*, Tab. Atenolol 50 mg and Placebo on D.B.P.

Croun	p Mean BT AT		Moon Diff	Moon 0/	n	cn	CE		n	Results
шопр	BT	ΑT	Mean Din.	Mean 70	11	30	3L	ι	Р	Results
Α	94.73	89.26	5.47	5.78	30	6.93	1.27	4.32	< 0.001	HS
В	95.40	88.20	7.20	7.55	30	4.830	0.882	8.16	< 0.001	HS
C	88.66	86.53	2.13	2.40	30	6.96	1.27	1.67	< 0.1	IS

In group A 30 patients were investigated for D.B.P. and an initial mean score of 94.73 mm of Hg D.B.P. was measured, after 2 month treatment of *Vyan Utkshepahara Ghan Vati* it reduced to 89.26 mm of Hg with a mean difference of 5.47 mm of Hg and 5.78% of relief. It is highly significant (t = 4.32, P < 0.001).

In group B's initial mean score D.B.P. was measured 95.40 mm of Hg and it reduced to 88.20 mm of Hg with 2 month treatment of atenolol

50mg and mean difference of 7.20 mm of Hg and 7.55 % of relief was observed. It is highly Significant (t = 8.16, P<0.001)

Initial mean score of group C's D.B.P. was measured 88.66 mm of Hg and after 2 month treatment of placebo is reduced to 86.53 mm of Hg and a mean difference of 2.13 mm of Hg was found and 2.40% of relief was found. It is insignificant (t = 0.1, P<0.001)




Table 3: showing mean percentage relief in Symptoms after two month clinical trial group, control group, and Placebo group.

S. No.	Group A	Group B	Group C
Sirahshoola	72.2%,	82.2%	20.63%
Bhrama	67.00%	83.13%	16.00%
Tinnitus	52.17%	77.77%	9.00%
Krodha	58.4%	61.9%	22.58%
Klama	53.12%	59.00%	15.87%
Hriddrava	58.33%	70.00%	14.28%
Anidra	53.48%	62.63%	11.62%
Swaskrichhrata	26.15%	61.90%	18.33%
Nishamutrata	40.00%	55.55%	19.04%
Bahumutrata	29.03%	58.49%	21.56%
Atisweda	28.57%	50.00%	19.23%

Table 4: show t value and P value of the symptoms after two month clinical trial (if P value<0.20 to >0.05=insignificant, if P value≤0.05 to >0.01=significant, if P value≤0.01 to <0.001= highly significant)

GROUP A			lts	GROUP E	3	lts	GROUP	lts	
Symptoms	t value	P value	Result	T value	P value	Resu	t value	P value	Results
Sirahshoola	10.43	<.001	H.S	12.49	<.001	H.S	1.47	<.10	I.S
Bhrama	9.74	<.001	H.S	12.81	<.001	H.S	1.58	<.10	I.S
Tinnitus	6.00	<.001	H.S	6.42	<.001	H.S	0.75	<.10	I.S
Krodha	9.34	<.001	H.S	12.80	<.001	H.S	1.66	<.10	I.S
Klama	5.57	<.001	H.S	7.94	<.001	H.S	1.55	<.10	I.S
Hriddrava	7.70	<.001	H.S	10.12	<.001	H.S	1.47	<.10	I.S
Anidra	8.02	<.001	H.S	12.85	<.001	H.S	1.44	<.10	I.S
Swaskrichhata	2.37	<.02	S	7.21	<.001	H.S	1.59	<.10	I.S
Nishamutrata	2.87	<.02	S	5.00	<.001	H.S	1.17	<.20	I.S
Bahumutrata	2.43	<.02	S	7.03	<.001	H.S	1.60	<.10	I.S
Atisweda	1.97	<.05	S	6.04	<.001	H.S	1.23	<.20	I.S

# **Bio-Chemistry Tests**

Table 6: showing the effect of Trial Drug (Vyan utkshepahara ghan vati) of Group A (Diabetes (NIDDM) induced hypertension).

S.No.	Test	Mean		Mean	Mean Mean %		SD	SE		Results
3.NO.	rest	BT	AT	Diff.	Mean %	11	SD	3E	ι	Results
1.	S. Cho.	175.73	158.53	17.2	9.78	30	17.40	3.17	5.41	< 0.001
2.	S. Tg.	150.33	143.00	7.33	4.87	30	9.80	1.78	4.09	< 0.001
3.	S. HDL	43.50	54.63	11.13	25.59	30	16.58	3.02	3.67	< 0.001
4.	S. LDL	88.00	83.66	4.33	4.92	30	10.06	1.83	2.35	< 0.02
5.	S. VLDL	33.56	30.1	3.46	10.32	30	8.88	1.62	2.13	< 0.02
6.	S.Creatinine	0.79	0.73	0.06	7.94	30	0.239	0.043	1.44	< 0.10
7.	S. Urea	32	28.66	3.33	10.41	30	10.30	1.88	1.77	< 0.05
8.	F.B.S.	116.20	102.66	13.53	15.69	30	16.73	3.05	4.43	< 0.001

 $Showing \ theeffect \ of \ Trial \ Drug \ (\textit{Vyan utkshepahara ghan vati}) \ of \ Group \ A$ 




Table 7: Showing the effect of control drug (Atenolol 50mg) on Group B.

S No	S.No. Test		an	Mean Diff.	Moan %	n	SD	SE	t	Results
3.110.	1630	BT	AT	Mean Din.	Mean 70	11	30	3E	٠	Results
1.	S. Cho.	171	166.4	4.6	2.69	30	16.64	3.03	1.51	< 0.10
2.	S. Tg.	148.66	144.53	4.13	2.78	30	14.64	2.67	1.54	< 0.10
3.	S. HDL	50.3	57.3	7.00	13.91	30	23.24	4.24	1.64	< 0.10
4.	S. LDL	95.63	93.13	2.49	2.61	30	10.90	1.99	1.25	< 0.20
5.	S. VLDL	33.56	30.8	2.76	8.24	30	9.63	1.75	1.57	< 0.10
6.	S.Creatinine	0.783	0.76	0.023	2.97	30	0.116	0.021	1.09	< 0.20
7.	S. Urea	32.06	29.13	2.93	9.14	30	10.32	1.88	1.55	< 0.10
8.	F.B.S.	80.73	78.66	2.07	2.55	30	8.70	1.59	1.29	< 0.20

# Showing the effect of $D_{13.91}$ (Atenolol 50 mg) on Group B





Table 8: showing the effect of Placebo Therapy on Group	С

S.No.	Test	Mean		Mean Diff.	Moan %	n	SD	SE	t	Results
3.110.	1631	BT	AT	Mean Din.	Mean 70	11	30	3E	·	Results
1.	S. Cho.	177.2	170.66	6.53	3.68	30	27.77	5.07	1.28	< 0.20
2.	S. Tg.	148.66	145.2	3.46	2.33	30	15.28	2.79	1.24	< 0.20
3.	S. HDL	57.46	54.5	2.96	5.16	30	13.37	2.44	1.21	< 0.20
4.	S. LDL	95.66	93.63	2.03	2.12	30	10.99	2.00	1.01	< 0.30
5.	S. VLDL	35.03	32.23	2.8	7.99	30	10.46	1.91	1.46	< 0.10
6.	S.Creatinine	0.786	0.766	0.020	2.54	30	0.112	0.020	1.00	< 0.30
7.	S. Urea	32.06	30.06	2.00	6.23	30	10.93	1.99	1.00	< 0.30
8.	F.B.S.	81.03	79.63	1.4	1.72	30	8.72	1.59	0.88	< 0.30



 $Table: 9 showing the effect of Trial\ Drug\ \textit{(Vyan\ utkshepahara\ ghan\ vati)}\ on\ Hb,\ TLC\ \&\ ESR\ in\ group\ A.$ 

Group	Took	Mean		Mean	Mean		CD	CE		n	Dogulto
	Test	BT	AT	Diff.	%	n	SD	SE	ι	þ	Results
A	Hb gm%	11.77	11.98	0.21	1.84	30	0.806	0.147	1.47	< 0.10	I.S
В	TLC	8046	7851	194	2.41	30	712	130	1.49	< 0.10	I.S
C	ESR	16.06	14.53	1.53	9.54	30	4.33	0.791	1.93	< 0.05	S

Table: 10 showing the effect Atenolol 50 mg on Hb, TLC & ESR  $\,$  in Group B.

C	T	Mean		M D:66	M 0/		CD	CE			Dogulto
Group	Test	BT	AT	Mean Diff.	mean %	n	SD	SE	τ	p	Results
A	Hb gm%	11.83	12.08	0.25	2.11	30	0.858	0.156	1.59	< 0.10	I.S
В	TLC	8004	7808	196	2.44	30	665.67	121.53	1.61	< 0.10	I.S
С	ESR	16.2	14.53	1.66	10.28	30	4.46	0.815	2.04	< 0.05	S

Table 11: showing effect of Placebo on Hb,TLC & ESR group C.

Group	Toot	Mean	Mean		Maam 0/		CD	CE			Results
	Test	BT	AT	Diff.	Mean %	n	SD	SE	ι	þ	Results
A	Hb gm%	11.86	12.10	0.233	1.96	30	1.00	0.183	1.27	< 0.20	I.S
В	TLC	8021	7886	135	1.68	30	614.76	112.24	1.20	< 0.20	I.S
С	ESR	16.2	15.06	1.13	6.99	30	4.86	0.887	1.27	< 0.20	I.S

**Biological values**: After two month of trial there are no significant changes in Hb and TLC. *Vyan utkshepahara ghan vati* and Control drug Therapy showed statistically significant decrease in ESR. (Table-9-10)

Table 12: showing the Percentage of striking, wonderful, nice and fair in all three groups in S.B.P.

C No	Dosnonso	No. of Patients with reduction in SBP									
5. NO	Response	Group A	n=30	%	<b>Group B</b>	n=30	%	<b>Group C</b>	n=30	%	
1.	Striking	9		30.00	15		50.00	0		00.00	
2.	Wonderful	15		50.00	10		33.33	1		03.33	
3.	Nice	5		16.66	4		13.33	2		06.66	
4.	Fair	1		03.33	1		03.33	17		56.66	
5.	No response	0		00.00	0		00.00	10		33.33	

Table 13: showing the Percentage of striking, wonderful, nice and fair in all three groups in D.B.P.

No. of Patients with reduction in DBP										
S. No	Response	Group n=30	A %	Group n=30	В %	Group n=30	С %			
1.	Striking	8	26.66	16	53.33	0	00.00			
2.	Wonderful	16	53.33	10	33.33	1	03.33			
3.	Nice	4	13.33	3	10.00	2	06.66			
4.	Fair	1	03.33	1	03.33	16	53.33			
5.	No response	1	03.33	0	00.00	11	36.66			

#### DISCUSSION

Ayurvedic treatment is a better remedy than Allopathic because generally Allopathic medicines are given after diagnosis of symptoms, whereas Ayurvedic remedies are given after analyzing the cause or root of the problem. To understand the various causes of hypertension from the Ayurvedic point of view it is necessary to understand its basic fundamental principles. Hypertension may also be classified according the main *Dosha* involved and its site of origin. The main site of *Vata* is the large intestine. When Vata and accumulates it can be absorbed into the blood increasing the qualities of Vata and causing constriction of the blood vessel walls. Constriction of the blood vessels may also be a result of Vata increasing due to psychological stress associated with fear, anxiety and insecurity. The small intestine is the main site of Pitta. If Pitta accumulates here it is absorbed into the circulatory system increasing the viscous, fatty oily qualities. Due to the increased viscosity, the blood exerts pressure on the blood vessels resulting in increased blood pressure. Pitta can also increase due to psychological stress related to anger, hate, envy and jealousy may be associated with increase blood pressure. Kapha type hypertension originates in the stomach being the main site of Kapha. Kledaka Kapha produced in the stomach in the form of gastric mucosal secretions that are responsible for the digestion of carbohydrates, starch and glucose. The end products of this phase are tryglycerides. When Kledaka Kapha is disturbed or there is an accumulation of *Kapha* at this site, there is an

accumulation of triglycerides and cholesterol. This accumulation of Kapha predominant qualities then move into the circulatory system causing an increase in the viscosity of plasma tissue within the blood resulting in increased pressure on the blood vessels. Ayurveda recognizes that the mind has a strong influence on the heart. If an individual is under psychological stress, this can lead to the onset of hypertension. Mental tension accumulates in the physical body via the brain which is the gateway between the mind and body. This function is governed by *Prana Vayu* and controls the autonomic nervous system which is responsible for blood pressure regulation. The brain normally programs the body by sending excitatory and inhibitory impulses to certain areas, and by regulating the balance of the autonomic and sensory motor components of the nervous system. When *Prana Vayu* is disturbed, hypertension can occur due to excessive sympathetic stimulation. Disturbed Prana Vayu also relates to all psychosomatic diseases which are caused by the unbalancing and disorganization of mental processes that proceed as though they were disconnected from our control. Hypertension may also be a result of heredity and lifestyle due to developed mental patterns of unwholesome living habits which

affect the circuits of the brain leading to hypertension. The perception or mind can affect our body's response and lead to a balanced or imbalanced state of health. Environmental stimulus creates impression on the mind which leads to psychological response effects on the body altering the following centres:

1-Limbic system 2-Hypothalamus 3-Neuroendocrine system 4-Long term Effect on Body 5-Altered Immune Function

An important factor to be considered when establishing the cause and reason for the manifestation of disease in a particular part of the body is the concept of *Khavaigunya*. *Khavaigunya* corresponds to a *Dhatu* or area of the body being more susceptible to disease or imbalance. This helps to understand why a particular tissue is affected and its origin. For example there may be a genetic predisposition in the family (*Beej Doshaja*), long standing or acute exposure to environmental, physical or psychological stressors causing the tissue to be inherently weak or weakened, which explains why that particular site has become vitiated. Therefore any disease can be caused by one particular *Dosha* or a combination of the three. When the *Dosha's* become aggravated through food, lifestyle or attitude, the nature of that substance leads to an increase of similar qualities inherent in the body and mind. The accumulation of these qualities according to *Ayurveda* is first stage of disease.

In more than 95% of cases of specific underlying causes of hypertension cannot be found (essential hypertension) the pathogenesis of essential hypertension is not clearly understood. Non modifiable risk factor like age, sex, genetic factor, ethnicity & modifiable risk factor like obesity salt intake, Saturated fat, alcohol, heart rate, physical activity, environmental stress, socioeconomic status, dietary fibers & other factor explain approximately 40 - 60 %.

5% of hypertensive patient have identifiable causes like endocrinal (Diabetes) renal, cardiovascular disease, & drugs induce etc.

Hence the constituents of these drugs are selected in a holistic approach for Diabetic induced hypertensive patients.

Shankhapushpi (convolvulus pluricaulis)-help to treat stress induced hypertension (C.N.S origin)

Punarnava (Boerhavia diffusa) - help to treat renal induced hypertension

Vacha (Acorus calamus) help to treat stress induced hypertension (C.N.S origin)

Shunthi (zingiber officinale) - help to treat Toxins induced hypertension

Kutaki (Picrohiza Kurroa) help to treat Blood volume induced hypertension.

Patol (Trichoasathes dioica) help to treat Diabetic induced hypertension

 ${\it Gugglu}$  (Commiphora mukul) - help to treat Obesity induced hypertension

Arjun (Terminalia arjuna) - help to treat cardiac induced hypertension Karela (Momordia Charantia) - help to treat Diabetic induced hypertension

Jamun (Syzygium Cumini) - help to treat Diabetic induced hypertension

 ${\it Gudhchi}$  (Tinospora Cardifolia) - help to treat auto immune induced hypertension

Dipana – Pacana drugs it is clear that Agnimandya is a prime factor for production of Hypertension. Dipana pacana drugs (Shunthi etc) improve the status of Agni.

Lekhana drugs having Srotosodhaka & weight reducing properties which help to treatment of hypertension. (Drugs like Guggulu Kutaki etc.)

Virechana: Kostha suddhi is very importance in treating a patient of Hypertension. The elimination of Doshas and Mala from body by Virechana karma, Virechana karma reduce the increase blood volume induced Hypertension. (Example Kutaki)

*Tridosha samana*: Hypertension is *Tridoshaja vyadhi* but most vitiated and dominant *Doshas* are *vata* & *kapha*, those drugs which have *Tridoshsamaka* properties use to treat hypertensive patient (*Drug like Shunthi*)

Rasayana Therapy:Rasayna help to protect *Oja*. Improve *Agni*,cleans the microcirulatory channels etc. all these developments help in producing tranquility of mind and thus reducing Hypertension, Rasayans (Chawanprash etc) increase the Medha (Buddhi) is called Medhya (drugs like shankhpuspi jatamansi etc.) help to treat stress induced hypertension.

*Srotosodhana: Rasayan like Guduchi* etc.*Mutrala* Drugs (Diuretics like *punarnava*) Reduce the vascular volume by diuresis which ultimately influence the blood pressure.

Hridya drugs (Cardiotonic) these drugs increase oja & Avalambaka Kapha. & are beneficial for heart is known as Hridya like Arjun etc. Uses of Antidiabetic drug like Karela in case of Diabetic induced Hypertension .Uses of guggulu preparation for obesity induced hypertension.

The result of the final study reveals better efficacy of *Vyan utkshepahara ghan Vati*. Fruther correlation in terms of S. Creatinine, S.Urea,and S.cholesterol etc. also confirms the efficacy of *Vyan utkshepahara ghan Vati*. The efficacy of *Vyan utkshepahara ghan Vati* in hypertension has been due to its ingredients; *shankhpuspi, punarnava, vacha, shunthi, kutaki, patol, gugglu, arjuna, karela, jamun shankhpusphi, punarnava, vacha, shunthi, kutaki, patol, gugglu, arjuna, karela, jamun and gudhchi directly or indirectly affects on blood pressure. The desired Pharmacological effect also shows the genuine nature of medicament. The present study being of explanatory nature no firm reacting result can be desired. Further study in this respect shall have the way to pin point role of all the drugs in Hypertension.* 

#### CONCLUSION

In all the three groups, group A (Diabetes (NIDDM) induced hypertension) was found as the most benefited group because it showed significant as well as highly significant changes in symptoms and Biochemistry investigations. Whereas Group B (control group) showed significant as well as highly significant changes in symptoms but not in Biochemistry investigations. Placebo showed insignificant changes in both.

The drug *Vyan utkshepahara ghan vati* is a safe herbal formulation and has shown encouraging results in the management of Diabetes (NIDDM) induced hypertension on various scientific parameters. While *Vyan utkshepahara ghan vati* reduced both systolic and diastolic

pressure in a more pronounced way, Furthermore, it was also found during treatment that some of patients improved to such an extent that they had either stopped the modern antihypertensive drug completely or minimized its dose suggesting that the drug. Thus being helpful in avoiding the side effects of modern drug too.

The plus point observed in case of *Ayurvedic* management is absence of any hazardous effect, which is really a great benefit to the patient.

It offers the possibility of effectiveness & very well tolerated therapy ensuring reliability & good acceptance in use therefore on point of view of *Ayurvedic* treatment by *Vyan utkshepahara ghan vati* may be accepted as the drug of choice in the case of mild and moderate Diabetes (NIDDM) induced hypertension.

## REFERANCES

- Alam, M.M: Siddiqui, M.B. & Husain, W. (1990), Treatment of diabetes through herbal drugs in rural India, Fitoterapia, Vol. 61 (3) PP.240-242.
- Anonymous (1950), the Wealth of India, Raw Materials, Council of Scientific and Industrial Research, Delhi, Vol. II, PP. 315.
- 3. Anonymous (1970), charaka Samhita. Commentary by Shastri, K.N. et al., chaukhambha Vidyabhavan, Varanasi, Ci.-1-1. 48, 58; 1-3, 24, 30, 31; 10. 62: 18.57.
- Anonymous (1976), Medicinal Plants of India. Indian Council of Medical Research, New Delhi, Vol. I, PP 276.
- Principle of epidemiology & epidemiologic methods. Park's Text book of preventive & social Medicine (chapter 3) Page 48-51, 56-58 Chapter 6, epidemiology of Chronic non communicable disease (SPM) and condition Page 309-313.
- Designing & Methodology of an experimental or A study chapter 13 Page 207 to 209 (Books method in Biostatistics written by B.K. Mahajan).
- Human Physiology written by Dr. A.K. Jain volume I Chapter 6,7,8,9 Page 315-350.
- 8. Treds in hypertension epidemiology in India (J. Hum Hypertens 2004) Pub Med Result.
- 9. Department of Medicine Monilek Hospital & Research centre Jawahar Nagar Jaipur.
- 10. High blood pressure (HT) at a glance http://www.medicinenet.com/High blood pressure/ articles/htm.
- 11. Data based Page 360-362 (Punarnava) Vacha 469-471) Shankhapushpi 433-437.
- Rajesh Dixit (Dravya guna Vijnana) Page 188-192 (Punarnava) Vacha 765-770.
- 13. P.J. Mehta's Practical Medicine Edition 2001 Page 39-42.
- 14. Chapter 35, Approach to the patient with Hypertension (Edition 14, Volume I) written by Gordon H Williams in Harrisson Test book of Medicine Page 202-205.
- Chapter 246 Hypertensive vascular disease written by Gordon H Williams in Harrison Test Book of Medicine Page 1380-1386 (Edition 14 volume I).
- Tartora Chapter 21 Cardio Vascular system: The blood vessels & Haemodynamics.
- 17. http://www.biospectrumasia.com/content/print articles.asp.
- 18. http://www.ncbi.nlm.mih.gov/pabmed/014730320.
- Concise medical physiology (Third edition) written by Dr. Sujit K. Chaudhuri Chapter 4, 5, 8, and 9.
- 20. Method of Biostatistics Mahajan B.K. Jaypee brother New Delhi.  $6^{\rm th}$  Edition 1997.
- Navanitaka Ed. from the editorial principles of the Dr. Hoernle by Balwant Singh Mohan Published by Mehar Chand Lachman Das (Lahore 1925.
- Padama Purana Translated & Annofated by N A Deshpandey Motilal Banarasidas Pvt. Ltd. Delhi vol. 41 Part III Ist Edition 1990.
- 23. Agrawal Et. al. 1956.

# Gupta et al.

# Innovare Journal of Ayurvedic Sci., Vol 1, Issue 1, 2013, 5-12

- 24. Charaka Samhita Pandit Kasinatha Shastri & Gorkhanath Chaturvedi, Publisher Chaukhambha Bharati Adcademy Varanasi 13th 1986.
- 25. Charaka Samhita RevisedBanan Shastri Academy Varanasi 1922.
- Ayurvedic Physiology2nd Vaidya Ranjeet Rai Desai, Nirnayasagar, Publisher Shri. Vaidyanatha Ayurveda Bhavana, Ltd. Patna 1953.
- 27. Sushruta Samhita12thYadavji Trikamji, Nirnayasagar Press1915.
- 28. Astanga Samgraha14hVriddha Vagbhatta, baidya Anant Damodar, Athvale, Shrimada Atreya Prakashan Pune1980.
- 29. Astanga Hridaya14thArun dutta, Harishastri Chaukhambha orientalia, Varanasi1982.
- Social and preventive medicine 16th K.Park Publisher Barsidas, Bhanot, Jabalpur1997.
- Text Book of Pathology 13thHarsha Mohan, JP Medical Publisher New Delhi1992.
- 32. Practical medicine 8th P.J.Mehta, Dr. S.P.Mehta1979.
- 33. Principles of Internal Medicine 12thHarisson's 1991.
- 34. Text Book of Medical Physiology7thGyton 1986.
- 35. Text Book of Medical Physiology 3rdChaudhari 1980.
- 36. Text Book of Medicine7thDavidson 1995.
- 37. Text book of preventive & social Medicine Park's 21th edition.
- 38. Biostatistics 6th B.K. Mahajan Jaypee brother New Delhi 1997.
- 39. Human Physiology7thDr. A.K. Jain1993.